GILD · 8-K · 20260804PR000028

Product Sales Performance

GILEAD SCIENCES, INC. · 2026-08-04 · Importance 52 · Surprise 56 · Contradicted

Biktarvy sales increased 7% year over year to $3.8 billion, driven by higher average realized price, favorable inventory dynamics and higher demand. Descovy sales increased 48% to $967 million, primarily because of higher average realized price and demand, including U.S. sales of $921 million versus $601 million. Trodelvy sales increased 26% to $457 million on higher demand, while Livdelzi sales increased to $167 million from $78 million. Cell Therapy sales decreased 14% to $417 million because of competition, including Yescarta down 12% to $346 million and Tecartus down 24% to $70 million.

Key facts

• Descovy sales in Q2 2026: $967 million, increased 48% compared to the same period in 2025 source
• Cell Therapy product sales in Q2 2026: $417 million, decreased 14% compared to the same period in 2025 source
• Trodelvy sales in Q2 2026: $457 million, increased 26% compared to the same period in 2025 source
• HIV product sales in Q2 2026: $5,693 million, increased 12% compared to Q2 2025 source
• Liver Disease portfolio sales in Q2 2026: $877 million, increased 10% compared to the same period in 2025 source
• Yescarta sales in Q2 2026: $346 million, decreased 12% compared to the same period in 2025 source
• Tecartus sales in Q2 2026: $70 million, decreased 24% compared to the same period in 2025 source
• Total second quarter 2026 product sales excluding Veklury: $7,604 million, increased 10% compared to the same period in 2025 source

Impact estimates